STU 3 Candidate

This page is part of the FHIR Specification (v1.4.0: STU 3 Ballot 3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4B R4 R3

Observation-example-genetics-3.xml

Raw XML (canonical form)

Genetics example 3 (id = "example-observation-genetics-3")

<Observation xmlns="http://hl7.org/fhir">
  <id value="example-observation-genetics-3"/>
  <text><status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example-observation-genetics-3</p><p><b>status</b>: final</p><p><b>code</b>: Further analysis <span>(Details )</span></p><p><b>subject</b>: <a>Molecular Lab Patient ID: HOSP-23456</a></p><p><b>issued</b>: 03/04/2013 3:30:10 PM</p><p><b>performer</b>: <a>Sequence Analysis Laboratory</a></p><p><b>comment</b>: The EGFR p.L858R mutation has been associated with response to anti-EGFR therapy</p><h3>Relateds</h3><table><tr><td>-</td><td><b>Type</b></td><td><b>Target</b></td></tr><tr><td>*</td><td>derived-from</td><td><a>ObservationForGenetics profile example 1</a></td></tr></table></div></text><status value="final"/>
  <code>
    <text value="Further analysis"/>
  </code>
  <subject>
    <reference value="Patient/example-genetics-somatic"/>
    <display value="Molecular Lab Patient ID: HOSP-23456"/>
  </subject>
  <issued value="2013-04-03T15:30:10+01:00"/>
  <performer>
    <reference value="Practitioner/example"/>
    <display value="Sequence Analysis Laboratory"/>
  </performer>
  <comment value="The EGFR p.L858R mutation has been associated with response to anti-EGFR therapy"/>
  <related>
    <type value="derived-from"/>
    <target>
      <reference value="Observation/example-observation-genetics-1"/>
      <display value="ObservationForGenetics profile example 1"/>
    </target>
  </related>
</Observation>

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.